A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
05 LLDAS is an excellent outcome measure, but does it really capture patients with true LDA?
2022
Lupus Science and Medicine
Learning Objectives . Describe the evidence base for current cyclophosphamidebased regimens . Discuss the advantages and disadvantages of using cyclophosphamide-based regimens . Explain how cyclophosphamide might be used in combination with newer therapies
doi:10.1136/lupus-2022-la.5
doaj:dbc1d254b53f469ba859e142a390b112
fatcat:v2elb3nnizaa7eznf3ilyovhie